There are currently 990 clinical trials in Tampa, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Moffitt Cancer Center, University of South Florida, H. Lee Moffitt Cancer Center and Research Institute and Tampa General Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study
NCT06016946
Recruiting
This project is a global, multicenter, prospective, longitudinal, observational natural history study that can be used to understand the disease progression and support the development of safe and effective drugs and biological products for Friedreich ataxia.
Gender:
ALL
Ages:
All
Trial Updated:
06/13/2025
Locations: USF Ataxia Research Center, Tampa, Florida
Conditions: Friedreich Ataxia
Register for Updates
Cocooned Moms Study
NCT06968650
Recruiting
The Cocooned Moms Study is a pre- and post-design study primarily aimed at reducing stress, depressive symptoms, and blood pressure among expectant Black women by providing them with free access to the InovCares mobile app. InovCares is a culturally-sensitive telehealth platform designed for community-based care coordination in maternal care. It also offers a culturally tailored maternal mental health program, which provides access to resources addressing social determinants of health, cognitive... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Dr.Traci's House, Tampa, Florida
Conditions: Stress, Depression, Pregnancy, Blood Pressure
Register for Updates
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
NCT03887715
Recruiting
Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity, based on multiple depression scale assessment tools at 12 months from randomization.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Stedman Clinical Trials, Tampa, Florida
Conditions: Treatment Resistant Depression
Register for Updates
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
NCT05099770
Recruiting
The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.
Gender:
ALL
Ages:
Between 30 years and 80 years
Trial Updated:
06/12/2025
Locations: Genesis Clinical Research, Tampa, Florida
Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Register for Updates
QTX3034 in Patients With KRAS G12D Mutation
NCT06227377
Recruiting
Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Solid Tumors
Register for Updates
A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease
NCT06307613
Recruiting
This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod PH20 SC in participants with active, moderate-to-severe TED, compared with placebo PH20 SC. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive efgartigimod PH20 SC or placebo PH20 SC, respectively during the double-blinded treatment period (DBTP). At the end of the DBTP, participants may enter a follow-up... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: University of South Florida (USF) Health - Morsani Center for Advanced Healthcare, Tampa, Florida
Conditions: Thyroid Eye Disease
Register for Updates
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
NCT06323928
Recruiting
The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these medications have not helped them.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/12/2025
Locations: K2 Medical Research Tampa LLC, Tampa, Florida
Conditions: Migraine
Register for Updates
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06558279
Recruiting
The purpose of this study is to evaluate the efficacy and safety of efgartigimod PH20 SC given by a pre-filled syringe in adult patients with ocular myasthenia gravis. The study consists of a part A (approximately 7 weeks) and a part B (up to 2 years). In part A, half of the participants will receive efgartigimod PH20 SC and the other half will receive placebo. In part B, all participants will receive efgartigimod PH20 SC. The participants will be in the study for about up to 2 years and 12 week... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: University of South Florida, Tampa, Florida
Conditions: Myasthenia Gravis, Ocular
Register for Updates
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
NCT06104592
Recruiting
This is a phase 2, single-arm, open-label study to evaluate the safety and efficacy of comprehensive bridging radiation therapy prior to CD19 CAR T-cell therapy for large B-cell lymphoma patients with bulky disease, defined as any lesion ≥5 cm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
Register for Updates
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
NCT06401421
Recruiting
The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: St. Joseph's Women's Hospital, Tampa, Florida
Conditions: Breast Cancer
Register for Updates
Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy
NCT06660355
Recruiting
Allogeneic transplant is potentially curative for hematological malignancies but its use is limited by the development of GVHD. Ruxolitinib now has FDA approval for treatment of chronic GVHD that has failed 1-2 prior lines of therapy based on a prior large, randomized phase III study. Given this evidence of safety and efficacy in the early refractory setting (after prednisone failure), Ruxolitinib represents an ideal agent to test in the primary therapy setting. Here investigators propose a phas... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Chronic Graft-versus-host Disease (cGVHD)
Register for Updates
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
NCT06684847
Recruiting
The main purpose of the proposed study is to evaluate the efficacy of efgartigimod PH20 SC in patients with moderate-to-severe Primary Sjögren's Disease (pSjD). The study consists of a double-blinded placebo-controlled treatment period and an open-label treatment period. The maximum study duration for participants in both study parts is approximately 105 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Clinical Research of West Florida, Inc., Tampa, Florida
Conditions: Primary Sjogrens Disease
Register for Updates